Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.92 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromobenzene SCHEMBL29116318 | 1.00 | ALDH1A1 (0.92) | ALDH1A1TDP1MAPK1CYP2A6HTR2A | |
| Bromobenzene SCHEMBL27532658 | 1.00 | — | — | |
| Bromobenzene SCHEMBL27338894 | 1.00 | — | — | |
| Bromobenzene SCHEMBL28159228 | 1.00 | ALDH1A1 (0.92) | ALDH1A1TDP1MAPK1CYP2A6HTR2A | |
| Bromobenzene SCHEMBL1736835 | 1.00 | ALDH1A1 (0.92) | ALDH1A1TDP1MAPK1CYP2A6HTR2A | |
| Bromobenzene SCHEMBL1736832 | 1.00 | ALDH1A1 (0.92) | ALDH1A1TDP1MAPK1CYP2A6HTR2A | |
| Bromobenzene SCHEMBL313507 | 1.00 | ALDH1A1 (0.92) | ALDH1A1TDP1MAPK1CYP2A6HTR2A | |
| Bromobenzene SCHEMBL6274950 | 0.96 | ALDH1A1 (0.85) | ALDH1A1TDP1MAPK1CYP2A6HTR2A | |
| Bromobenzene SCHEMBL537562 | 0.96 | ALDH1A1 (1.00) | ALDH1A1TDP1MAPK1CYP2A6HTR2A | |
| Bromobenzene SCHEMBL1331176 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12406696-B2 | Photopolymer compositions for thermostable photopolymers in the visible spectral range | COVESTRO DEUTSCHLAND AG (DE) | 2025-09-02 | — | — | US | disclosed |
| US-20250182787-A1 | Photopolymer Compositions for Thermostable Photopolymers in the Visible Spectral Range | COVESTRO DEUTSCHLAND AG (DE) | 2025-06-05 | — | — | US | disclosed |
| US-20250171648-A1 | Thermostable Photopolymers in the Visible Spectral Range and Photopolymer Compositions Containing Same | COVESTRO DEUTSCHLAND AG (DE) | 2025-05-29 | — | — | US | disclosed |
| CN-118742959-A | Thermally stable photopolymers in the visible spectrum and photopolymer compositions comprising same | 科思创德国股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-118742960-A | Photopolymer composition of thermally stable photopolymer in the visible spectral range | 科思创德国股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-115461327-A | Spiro urea derivatives | 爱杜西亚药品有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-105541769-A | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC | 2016-05-04 | — | — | CN | disclosed |
| CN-103664637-B | Be used for the treatment of ophthalmic diseases and disorderly alkynyl phenyl derivative compounds | ACUCELA INC. (US) | 2016-02-03 | — | — | CN | disclosed |
| CN-103664637-A | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC | 2014-03-26 | — | — | CN | disclosed |
| CN-101784188-B | Alkynyl phenyl derivative compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2014-02-12 | — | — | CN | disclosed |
| CN-101443323-A | Substituted spirocyclic CGRP receptor antagonists | MERCK & CO INC (US) | 2009-05-27 | — | — | CN | disclosed |
| US-7141598-B2 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2006-11-28 | — | — | US | disclosed |
| EP-1681290-A2 | Imidazole derivatives, production method thereof and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2006-07-19 | — | — | EP | disclosed |
| EP-1334106-B1 | IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-20050043544-A1 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
| EP-1471056-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-20040033935-A1 | Novel imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1334106-A2 | NOVEL IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002040484-A2 | NOVEL IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-23 | — | — | WO | disclosed |
| US-4593047-A | Alcoholism | RICHTER GEDEON VEGYESZETI CYAR RT (HU) | 1986-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033935-A1 | Novel imidazole derivatives, production method thereof and use thereof | CYP17A1, CYP21A2, CYP19A1 | ALDH1A1 227/4885TDP1 2019/4885MAPK1 2678/4885 |
| US-20050043544-A1 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | CYP17A1, HSD17B7, HSD17B1 | ALDH1A1 1246/4885TDP1 4649/4885MAPK1 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.